The Immune Response Corporation

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 4, 2023
Human, AACR, PD, Half-life, Safety, Biotechnology, 3D, Cancer, Research, Cmax, Mutation, Initial, American Association for Cancer Research, Patient, RAS, Administration, China Bio-Immunity Corporation, Toxic Substances Control Act of 1976, Research and development, R, IND, Pharmaceutical industry, Life insurance, The Immune Response Corporation

We now expect to announce a recommended Phase 2 dose in early 2024, which provides us an opportunity to assess potential preliminary efficacy earlier than anticipated.

Key Points: 
  • We now expect to announce a recommended Phase 2 dose in early 2024, which provides us an opportunity to assess potential preliminary efficacy earlier than anticipated.
  • 2023 is shaping up to be a breakout year for Immuneering as we continue to expeditiously advance IMM-1-104 in the clinic.
  • Chief Business Officer appointed: In March 2023, the company announced the appointment of Harold E. Brakewood (“E.B.”) as its Chief Business Officer.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter ended 2023, were $10.2 million compared with $9.1 million for the first quarter of 2022.

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

Retrieved on: 
Tuesday, March 28, 2023
MSD, Neoplasm, Biotechnology, Cancer, MAPK, MBA, Dartmouth College, Strategic planning, The Immune Response Corporation, COVID-19, Patient, RAS, Bowdoin College, Harvard Business School, Physics, China Bio-Immunity Corporation, Merck, Cemiplimab, Pharmaceutical industry, Regeneron Pharmaceuticals, Pembrolizumab

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E. Brakewood (“E.B.”) as its Chief Business Officer.

Key Points: 
  • CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E. Brakewood (“E.B.”) as its Chief Business Officer.
  • Mr. Brakewood, who has more than 25 years of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development, new product planning, and commercial strategy.
  • join Immuneering’s senior leadership team as we continue to advance our oncology pipeline, including IMM-1-104, our clinical-stage universal-RAS program,” said Ben Zeskind, Ph.D., MBA, Co-founder, and Chief Executive Officer of Immuneering.
  • He joins Immuneering from Regeneron Pharmaceuticals where he most recently served as Vice President, Business Unit Head for oncology, Covid-19, and new product planning.

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

Retrieved on: 
Thursday, March 23, 2023
Diabetic neuropathy, US, HIV, Triclonella sequella, JAN, Risk, PAD, International, CRPS, Doctor of Philosophy, The Immune Response Corporation, LAS, Pain, Peripheral artery disease, Running, Pain management, Security (finance), Neuro, FDA, Chronic pain, Consultant, Pharmaceutical industry, Management, Bonfiglio, Janon

LAS VEGAS, March 23, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio, PhD, as interim president of its JanOne Biotech subsidiary. JanOne Biotech focuses on pain management for diabetic neuropathy, Peripheral Artery Disease (PAD), and other chronic pain conditions using innovative treatments developed by JanOne Inc.

Key Points: 
  • Dr. Bonfiglio is a veteran leader in the biotech industry with a track record of raising capital, building start-ups and excelling in C-suite roles.
  • After spending his early career at Allergan Pharmaceuticals and Baxter HealthCare, he turned to discovering, promoting and leading smaller biotech ventures.
  • Currently he is a board member for Avipero and executive board member for Sequella, a US- based biotech company.
  • Dr. Bonfiglio expressed his "goals for collaborating with the well-respected scientific team at JanOne."

EQS-News: Immunic to Participate in Investor and Scientific Conferences in March

Retrieved on: 
Thursday, March 2, 2023
Biotechnology, Virology, CET, Society, American Academy of Dermatology, Webcast, MPXV, AAD, American Academy, Pharmaceutical industry, The Immune Response Corporation

NEW YORK, March 2, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:

Key Points: 
  • NEW YORK, March 2, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:
    March 9: BioCapital Europe.
  • Specific details regarding webcast and replay information will be published on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations , once they are available.
  • Andreas Muehler, M.D., Chief Medical Officer of Immunic, will attend this conference in New Orleans, Louisiana.
  • Members of Immunic’s preclinical team and its collaboration partners have been accepted to present three posters at this conference in Ulm, Germany.

Immuneering Announces Participation in March Investor Conferences

Retrieved on: 
Tuesday, February 28, 2023
China Bio-Immunity Corporation, Panel discussion, CPA, Cancer, Entrepreneurship, Conference, Patient, The Immune Response Corporation, Pharmaceutical industry, Finance

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company’s pipeline, platform, and business strategy.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will participate in two March investor conferences to share commentary around the company’s pipeline, platform, and business strategy.
  • Participating will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.
  • Immuneering will participate in the following investor conferences:
    Cowen 43rd Annual Health Care Conference (March 6 – 8, 2023)
    Panel Discussion: Titled ‘Targeted Oncology’ on March 7 from 2:10 to 3:10 p.m.
  • ET
    Oppenheimer 33rd Annual Healthcare Conference (March 13 – 15, 2023)
    Virtual Presentation: March 14 from 2:40 to 3:10 p.m.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in November and December

Retrieved on: 
Friday, November 11, 2022
Private Securities Litigation Reform Act, Stanford University, CET, DHODH, Risk, U.S. Securities and Exchange Commission, ISI, Lead, Nasdaq, Regeneration, Webcast, Royal Adelaide Hospital, Department, Multiple sclerosis, COVID-19, Stanford University School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Doctor of Philosophy, Institute, SEC, Annual report, Degenerative disease, Saunders family, CA, Time, Evercore, Drug development, CRO, Mount Sinai Hospital, Clinical trial, Conference, Psoriasis, University, NEW, Pediatrics, Security (finance), Icahn School of Medicine at Mount Sinai, Society, Metabolism, APSA, Pharmaceutical industry, Genetics, Neurology, The Immune Response Corporation

Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

Key Points: 
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available on the Events and Presentations section of Immunics website at: ir.imux.com/events-and-presentations .
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Immunic to Participate in Investor and Scientific Conferences in November and December

Retrieved on: 
Thursday, November 10, 2022
Private Securities Litigation Reform Act, Stanford University, DHODH, CET, Risk, U.S. Securities and Exchange Commission, ISI, Lead, Regeneration, Webcast, Royal Adelaide Hospital, Department, Multiple sclerosis, Stanford University School of Medicine, COVID-19, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Doctor of Philosophy, Institute, SEC, Annual report, Degenerative disease, Saunders family, CA, Time, Evercore, Drug development, Mount Sinai Hospital, Clinical trial, Conference, Psoriasis, University, University of Münster, Pediatrics, Security (finance), Icahn School of Medicine at Mount Sinai, Society, Metabolism, APSA, Pharmaceutical industry, Vaccine, Genetics, Neurology, The Immune Response Corporation

Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

Key Points: 
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat at this conference in New York on Thursday, December 1, 2022 at 12:30 pm ET.
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.

Immuneering Appoints Leah R. Neufeld as Chief People Officer

Retrieved on: 
Thursday, October 20, 2022
People, U.S. Securities and Exchange Commission, Therapy, American, MEK, Growth, Intercept Pharmaceuticals, Leah, Johnson & Johnson, Human, Patient, Drug development, 3D, Psychology, Entrepreneurship, RAS, Johns Hopkins University, Jiangsu Hengrui Medicine, Cancer, American University, Acquisition, Industry, Eli Lilly, NPS, Chemistry, GLOBE, Human resources, Forward-looking statement, MAPK, Shire (pharmaceutical company), China Bio-Immunity Corporation, Risk, Pharmaceutical industry, Pharma, IND, The Immune Response Corporation

Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people, stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.

Key Points: 
  • Our world-class team of Immuneers enables us to accomplish great things, and in Leah we now have a Chief People Officer worthy of our people, stated Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering.
  • Leah is a seasoned human resources leader with decades of experience in the life sciences industry.
  • Ms. Neufeld joins Immuneering from Luzsana Biotechnology, where, since August 2021, she served as Chief Human Resources Officer, and as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines, the largest Pharma company in China.
  • Prior to that, from 2015 through 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals.

Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights 

Retrieved on: 
Wednesday, August 10, 2022
U.S. Securities and Exchange Commission, China Bio-Immunity Corporation, ASCO, CRC, Forward-looking statement, GLOBE, R, Growth, Cancer, The Immune Response Corporation, RAS, Research, Research and development, NSCLC, Neoplasm, MAPK, Patient, Pancreatic cancer, TGI, G&A, Risk, NASDAQ, BRAF, KRAS, GAAP, Chemistry, MEK, MBA, Mutation, Administration, NRAS, KSR, Pharmaceutical industry, Cryptocurrency, IND

CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights. 

Key Points: 
  • IMM-1-104 IND submission expected this quarter: Immuneering remains on track to file its IND for IMM-1-104 this quarter.
  • Research and Development (R&D) Expenses: R&D expenses for the second quarter ended June 30, 2022 were $8.0 million, compared with $7.0 million for the same period in 2021.
  • General and Administrative (G&A) Expenses: G&A expenses for the second quarter ended June 30, 2022 were $3.7 million, compared with $1.3 million for the same period of 2021.
  • Net Loss: Net loss attributable to common stockholders was $11.5 million, or $0.44 per share, for the second quarter ended June 30, 2022, compared to $8.0 million, or $1.61 per share, for the second quarter ended June 30, 2021.

Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights 

Retrieved on: 
Tuesday, May 10, 2022
Forward-looking statement, Mutation, GAAP, 3D, U.S. Securities and Exchange Commission, NASDAQ, GLOBE, Chemistry, Sustainability Accounting Standards Board, Neoplasm, BRAF, Comparison, China Bio-Immunity Corporation, Research, MAPK, Patient, Doctor of Philosophy, Binimetinib, RAS, Administration, NEMO, NRAS, Cancer, Risk, Social responsibility, Dacarbazine, Research and development, R, MBA, G&A, Growth, KRAS, ESG, Sustainability accounting, Therapy, KSR, Pharmaceutical industry, The Immune Response Corporation, IND, Discovery

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights. 

Key Points: 
  • To date, we have generated compelling preclinical results across a broad range of animal tumor models including KRAS-G12C, KRAS-G12D, KRAS-G12S, NRAS-Q61R, and BRAF-V600E mutations.
  • Immuneering also hosted a key expert event with Dr. Anna Pavlick, a leading melanoma expert, to discuss the NRAS mutant melanoma treatment landscape.
  • Immuneering Published Its First Environmental, Social, and Governance (ESG) Report on March 31, 2022: The company published its first annual ESG report which highlights the companys commitment to corporate social responsibility.
  • IMM-1-104 IND submission expected in Q3 2022: Immuneering expects to file the IND for IMM-1-104 in the third quarter of 2022 and expects to enroll the first patient in its Phase 1 trial evaluating IMM-1-104 in the fourth quarter of 2022.